Singapore/ US based TurtleTree ready to commercialize Human Lactoferrin as first major product
Comunicato Precedente
Comunicato Successivo
Max Rye, Chief Strategist of TurtleTree shares "We have been able to identify early commercial ingredient targets due to our frequent conversations with prominent performance nutrition and infant formula companies. We've since seen tremendous interest from global partners in our portfolio of human and bovine milk products. It is going to be an exciting year for us."
Lactoferrin has been gaining significant traction recently in studies showing it's value in boosting resistance to infections from blocking COVID-19 virus to fighting off bad bacteria in the gut and viral infections. Lactoferrin is an important compound for babies' early protection, with its concentration in human milk is 5 times higher than in cow milk, while human colostrum has the highest amount of 5-6g/L.
Besides providing protection, lactoferrin also plays an important role in brain development and inflammation responses. Gaining traction for adult and senior health, today it is used for treating stomach and intestinal ulcers, diarrhea, hepatitis C and regulating the way the body processes iron.
Today's lactoferrin is derived from cow milk, now TurtleTree's cell based technology has recreated the human-optimized protein from the blueprint of human milk and makes it more accessible to everyone.
TurtleTree's mission has always been about nourishing our people and being kind to the planet. And we are now very excited to bring to the world our first product that is better-for-you without relying on cattle farming.
Contact:
TurtleTree Max Rye
Chief Strategist and Co-Founder
Phone: (760) 808-4652
Email: [email protected]
Photo - https://mma.prnewswire.com/media/1526431/Human_Lactoferrin_Powder.jpg
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




